Hyglos GmbH - a bioMérieux company - is a biotech company located in Biotechnology Center Bernried, Munich area, Germany. Being an IAFP Innovation Awardee we develop highly specific bacteriophage-derived proteins for improved detection and removal of harmful bacteria and bacterial toxins such as endotoxins. As a company we have a strong focus on innovation in the field of Endotoxin Detection. Our sustainable assays are based on Phage Recombinant Proteins and Recombinant Horseshoe Crab Factor C (rFC), completely without using the blood from horseshoe crabs. 

Since 1 July 2016, our endotoxin test methods are included in Chapter 5.1.10 of the European Pharmacopoeia as approved alternative methods.

Our endotoxin tests EndoLISA® and EndoZyme® bring important advantages to users in biopharmaceutical research and industry, overcoming limitations of the LAL test (Limulus amebocyte lysate) which still relies on lysate from the blood of the horseshoe (Limulus) crab. In 2014, Hyglos first introduced the Endo-RS® Endotoxin Recovery Method, overcoming Masking of Endotoxin which causes Low Endotoxin Recovery (LER) addressed by the FDA.

Follow Hyglos:

EndoLISA Video User Guide: